# Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）

Study · id `cardio:ct-nct05795517` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05795517](<https://clinicaltrials.gov/study/NCT05795517>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05795517

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

## Technical summary

Registry record NCT05795517. Randomized; double masking; primary purpose treatment. Start 2023-04-26 (actual); primary completion 2024-02-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 210 participants (enrolled count; ClinicalTrials.gov record NCT05795517, source copy `cardio:ctgov-nct05795517-2024-04-09`, retrieved 2026-10-31)
- Started: 2023-04-26 (actual) (ClinicalTrials.gov record NCT05795517, source copy `cardio:ctgov-nct05795517-2024-04-09`, retrieved 2026-10-31)
- Primary completion: 2024-02-20 (actual) (ClinicalTrials.gov record NCT05795517, source copy `cardio:ctgov-nct05795517-2024-04-09`, retrieved 2026-10-31)
- Completion: 2024-03-01 (actual) (ClinicalTrials.gov record NCT05795517, source copy `cardio:ctgov-nct05795517-2024-04-09`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT05795517, source copy `cardio:ctgov-nct05795517-2024-04-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05795517-2024-04-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）
- Condition: Hypercholesterolemia
- Intervention (Drug): HSK31679 low dose
- Intervention (Drug): HSK31679 medium dose
- Intervention (Drug): HSK31679 high dose
- Intervention (Drug): Placebo
- Intervention (Drug): Ezetimibe 10mg
- Lead sponsor: Haisco Pharmaceutical Group Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial (`cardio:pubmed-40846146`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f029eaa7771753d66cc6a9728f18a7e18743d8502e9fd0fb23baefd35d5f44b5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
